There's no discounting the importance of an approval from the Food and Drug Administration when it comes to pharmaceutical investing, particularly when you're dealing with small-cap stocks with few -- if any -- commercialized drugs. While United Therapeutics' (Nasdaq: UTHR ) classification falls somewhere between a big-pharma stalwart and feeble clinical-stage, an upcoming FDA approval decision regarding its pulmonary arterial hypertension drug Remodulin is an important development to watch.
In the following video, health care bureau chief Brenton Flynn and analyst David Williamson discuss the situation in more detail, and how it has repercussions for another small-cap pharma stock.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.